A tale of two triplets: tafasitamab, rituximab, lenalidomide and epcoritamab, rituximab, lenalidomide in relapsed/refractory follicular lymphoma.

Rituxan (rituximab) - Roche

lenalidomide - Generic mfg.

Epkinly (epcoritamab-bysp) - Genmab, AbbVie

Monjuvi (tafasitamab-cxix) - Incyte

A tale of two triplets: tafasitamab, rituximab, lenalidomide and epcoritamab, rituximab, lenalidomide in relapsed/refractory follicular lymphoma. (PubMed, Expert Opin Biol Ther) - Oct 8, 2026 - No abstract available
Journal • Follicular Lymphoma • Hematological Malignancies • Lymphoma • Oncology

http://www.ncbi.nlm.nih.gov/pubmed/42841619

Allison Karabinos; Donald C Moore; Katelynn Granger; Leah Galloway; Meagan Reinfried; Taylor S White

Oct 8, 2026